Transcript of The (AFL) Footy Show, Melbourne , Channel 9, 2 June 2005
 

Interview with Mesoblast Founder and Chief Scientific Adviser, Professor Silviu Itescu

EDDIE McGUIRE – PRESENTER :

On the back of that story is an interesting story now, the world of stem cell research. Now, we know that there have been a lot of moral and ethical issues in regards to embryonic stem cells. The area we're going to talk about for a few moments is actually adult stem cells. So, they don't have the same ethical problems or moral dilemmas that have been written about extensively in the media over the last couple of years.

Adult stem cell therapy is an area that is going to become more and more reality in the world of medicine coming forward.

We've asked Professor Silviu Itescu who's the Professor of Medicine at Melbourne University and the Columbia University in New York , and served on US President George W Bush's Council on Bioethics. He's also the founder of a company, a publicly listed company called Mesoblast, that's involved in the stem cells. Professor, welcome aboard.

SILVIU ITESCU

Good evening.

McGUIRE :

What is the future of stem cells, adult stem cells in relation to injuries like Nathan's had, and, also, maybe even soft tissue injuries going forward? Where are we heading in the world of medicine and sport and, for that matter, life in general?

ITESCU :

Well, let me say at the outset that I think Nathan's treatment has been first rate. Really, he's received everything that's currently available, has been treated on by an outstanding orthopaedic surgeon Hayden Morris

Really, the treatment that he has received is to just put his bones into an alignment and allow those few stem cells that are inside the bone to create new bone and repair the fracture. And, in most situations, that actually works.

Unfortunately, as you get older, you start to have less and less of your own adult stem cells, and in situations such as his kind of fracture where you've got a very severe break, there may not actually be enough stem cells to allow this repair process to occur.

ITESCU :

And the technology that Mesoblast is currently developing is based on more than 10 years of research at the Hanson Institute in Adelaide by world leading scientists, who identified these very precise adult stem cells, had developed ways of purifying these cells, growing them up in very large numbers, and really allowing us to take these cells and put them into those fractures in million-fold levels greater than they are presently today.

NEWMAN :

So Prof , is your charter eventually to ideally have a donor bank of stem cells that players or sports people put in when they sign up, and if this injury happens like it did to Nathan Brown, you can go to the bank, bring out their cells… is that the idea of it? And he would be fixed in half the time; is that it or not?

ITESCU :

Well, that's certainly an interesting idea. I think, where we are today is we're beginning clinical trials in patients with what's called delayed healing of fractures.

Again, as I say, in most cases, and certainly we hope that in Nathan's situation he's going to have a very smooth process, he'll have a complete recovery.

NEWMAN :

But if your thing was up and running, you could go to his stem cell bank and fix him within half the time?

ITESCU :

What we would hope is that if these stem cells are available as we move forward, these will be able to be used freshly at the time of a fracture and perhaps accelerate and help heal the fracture.

NEWMAN :

And lessen the risk of infection.

ITESCU :

Reduce the risk of infection, reduce the time to healing and reduce the period off sick.

McGUIRE :

Nick?

RIEWOLDT :

Are you facing any moral objections like there have been, you know, with …

NEWMAN :

Cloning.

RIEWOLDT :

… lots other, sort of, stem cell research?

McGUIRE :

Yeah, embryonic.

ITESCU :

No, I think it's really important to emphasise that these are adult stem cells. They're your own cells; they have nothing to do with embryonic stem cells. The big advantage here is that there are no ethical issues, no constraints, and there are no risks of cancer formation as, obviously, is a possibility with embryonic stem cells. So no, the answer is there are no ethical issues at all.

McGUIRE :

All right. Well, thanks very much, Professor. Very interesting that to hear what's happening.

Oh hello, Trev, yes.

MARMALADE :

Oh, I thought I'd put my Gilligan hat on. It's like Gilligan's Island here tonight isn't it? We've got the Professor, two millionaires, two skippers and a head hunter.

[Laughter and applause]

McGUIRE :

I'll be Thurston , so long as he's Lovey.

[Laughter]

Thanks …

NEWMAN :

Well, I'm looking forward to it whatever it is.

McGUIRE :

(Laughs) Thanks Professor, and …

NEWMAN :

Yeah, thanks Prof.

McGUIRE :

… It's interesting to see what happens. At the moment, it's about $20,000 Australian though isn't it, but obviously coming down as we go.

ITESCU :

We hope to make it a lot cheaper and accessible to many people who have these kinds of bone cartilage diseases of older age and degeneration.

McGUIRE :

All right.

END OF SEGMENT

 

For further information, please call:

Julie Meldrum
Mesoblast Limited
0419 228 128
julie.meldrum@mesoblast.com

>>back to What They Say

 

 

Last Share Price

14 February 2011 – Mesoblast Issues New Equity to Cephalon, Receives Further Cash Injection

9 February 2011 – Chairman’s Address, CEO Presentation to EGM

31 January 2011 – Mesoblast Reports Strong Cash Position; Appendix 4C Quarterly Cash Flow Report

12 January 2011 Mesoblast – Cephalon Alliance Highlighted at JP Morgan Healthcare Conference

10 January 2011 - Interim Results from Mesoblast’s Phase 2 Heart Failure Trial Shows “Off-the-Shelf” Proprietary Adult Stem Cell Product Revascor Reduces Cardiac Events, Mortality, and Hospitalization

23 December 2010 – Mesoblast Completes Acquisition of Angioblast

8 December 2010 – Mesoblast and Cephalon Enter into Strategic Alliance to Commercialize Novel Therapeutic Products for Regenerative Medicine

29 November 2010 – Building a solid futurec

19 November 2010 – Mesoblast Clear to Proceed with Angioblast Acquisition

16 November 2010 – Positive Results of Novel Heart Attack Treatment Presented at Premier USA Cardiology Conference

8 November 2010 - U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products

29 October 2010 - Notice of AGM

29 October 2010 - Mesoblast Annual Report 2010

21 October 2010 – Positive Results from Phase 2 Lumbar Fusion Trial Presented at International Investor Conference

20 October 2010 - Mesoblast Acquisition of US Company Approved by Angioblast Stockholders

14 October 2010 – Mesoblast targets broader cancer indications for bone marrow transplant product

23 September 2010 – Boardroom radio interview with CEO Silviu Itescu

22 September 2010 - Acquisition of US Company Ratified by Mesoblast Shareholders

22 September 2010: Results of Extraordinary General Meeting

22 September 2010 – Chairman Speech & CEO Presentation to EGM

20 September 2010 – Mesoblast Featured at International Scientific Conferences

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

30 November 2010 - Nomura Research; Mining the Marrow

22 November 2010 - Nomura Research: Mesoblast [MSB AU] - BUY: Trial Results Continue to Impress

16 November 2010 - Nomura Research: Mesoblast Buy: Releases Positive Clinical Trial Data in Heart Disease; NPV $19

8 October 2010 – Nomura Research: Updating forecasts for Angioblast

10 September 2010 - Southern Cross Equities Note to Clients : Mesoblast No. 1 Biotech Recommendation

10 September 2010 - Bioshares Analysis: Mesoblast Continues to Open New Product Opportunities

26 August 2010 - Nomura Global Equities Research: FY 2010 Making Their Bones

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

6 July 2010 - Nomura Global Equities Research: A Biotech Platform Technology; Anchor Report

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine